Anti-Melanin [8C3], Rabbit IgG, Kappa 貨號Ab02814-23.0

Anti-Melanin [8C3]由Protein A親和純化(濃度1mg/ml)，免疫原：抗體是用黑色素免疫雌性BALB/c小鼠 (黑色素顆粒由 Paracoccidioides brasiliensis L-DOPA 誘導的酵母細胞提取, 懸浮在 1:1 中(vol/vol) 不完全弗氏佐劑的乳液)特異性：該抗體結合黑色素。黑色素是一種存在於大多數生物體內的天然色素在稱為黑素細胞的特殊細胞群中產生。

Alternative Name(s) of Target: CHEBI:89634

Immunogen: 

The original antibody was generated by immunizing female BALB/c mice with melanin particles extracted from Paracoccidioides brasiliensis L-DOPA-induced yeast cells suspended in a 1:1 (vol/vol) emulsion of incomplete Freund adjuvant.

Specificity:

This antibody binds melanin. Melanin is a natural pigment found in most organisms is produced in a specialized group of cells called the melanocytes.

Application Notes: 

Paracoccidioides brasiliensis is the agent of the human systemic disease paracoccidioidomycosis. The binding characterization of this antibody towards melanin from various organisms was done using ELISA. This antibody was also used in the immunofluorescence analysis of P. brasiliensis melanized yeast cells (with l-DOPA induction) and wild-type conidia (PMID: 21813659). 213Bismuth and 177Lutetium labelled humanized 8C3 antibody was used in the radioimmunotherapy (RIT) of experimental B16-F10 melanoma (PMID: 31323785). It was demonstrated that a combination of humanized anti-melanin antibody conjugated to 213Bismuth and anti-PD-1 ICB reduced tumor growth and increased survival in the Cloudman S91 murine melanoma DBA/2 mouse model (PMID: 31991626). Male Cloudman S91-bearing DBA/2 mice when treated intraperitoneally with a combination of anti-PD-1 alone or low-dose humanized anti-melanin antibody conjugated to177Lutetium RIT alone resulted in modest tumor reduction, while their combination significantly reduced tumor growth and increased survival, suggesting synergy (PMID: 33218169).

Antibody first published in: 

Urán et al. Detection of antibodies against Paracoccidioides brasiliensis melanin in in vitro and in vivo studies during infection Clin Vaccine Immunol. 2011 Oct;18(10):1680-8. PMID:21813659

Absolute Antibody 成立於 2012 年，其願景是讓所有人都能獲得工程重組抗體(engineered recombinant antibodies)，我們仍然是唯一一家 100% 專注於重組抗體技術(recombinant antibody technology)的公司。儘管重組抗體(recombinant antibodies)是製藥行業(pharmaceutical industry)的標準，但這些抗體並未廣泛用於診斷或研究。然而，由於重組抗體比傳統的雜交瘤產生的單克隆抗體(hybridoma-produced monoclonal antibodies)具有許多優勢。Absolute Antibody 一直處於使所有人更容易獲得重組抗體的運動的最前沿。 2015 年，在一篇關於標準化研究抗體的必要性的 Nature 論文中得到認可，2018 年，Absolute Antibody與co-authored著了一篇 mAbs Journal 論文，進一步說明了使用重組抗體的重要性。多年來，隨著對重組抗體的需求增加，Absolute Antibody迅速成長。

我們專注於抗體測序(antibody sequencing)、工程(engineering)和重組表達(recombinant expression)，提供royalty-free custom services定制服務和獨特的工程重組抗體和 Fc 融合蛋白試劑(c Fusion proteins)目錄。Absolute Antibody的客戶包括全球領先的製藥、生物技術和診斷公司，以及全球的學術研究人員；Absolute Antibody在 65 個不同的國家擁有客戶，並已向收入排名前 15 位的製藥公司中的 14 家銷售產品。Absolute Antibody在英格蘭東北部獲得 ISO 9001:2015 認證的製造工廠以及在美國波士頓和荷蘭阿姆斯特丹的其他辦事處為這一國際客戶群提供服務。

Absolute Antibody 團隊在治療性抗體(therapeutic antibody)和重組技術recombinant technology領域擁有豐富的經驗。Absolute Antibody共同擁有提供高質量產品和服務的知識和專業知識，並為客戶的抗體開發項目提供高水平的諮詢。自成立以來，Absolute Antibody已為客戶生產了 140 多種不同的抗體形式，並開發了包含 11,000 多種工程重組抗體的試劑目錄。例如，查看一個目錄克隆（抗 EGFR 或西妥昔單抗），有 30 多種不同的現成格式。

僅 2021 年，Absolute Antibody就對 1200 多個雜交瘤進行了測序(sequenced)，成功完成了 30 個抗體人源化(antibody humanization projects)項目，生產了 3500 多種不同的抗體，總共生產了 160 克蛋白質。 2020 年，Absolute Antibody憑藉快速的國際擴張獲得了國際貿易企業女王獎(Queen’s Award)。我們期待繼續這種增長，並朝著我們為所有人設計的重組抗體的願景而努力​​。

Fc Silent™ 抗體

Fc Silent™ 代表 Absolute Antibody 開發的基因工程 Fc 域，用於研究和檢測開發。它包含消除 Fc 受體 (FcγR、FcR) 結合的關鍵點突變，消除抗體定向細胞毒性 (ADCC) 效應器功能。Fc Silent™ 抗體使研究人員能夠在體內去除效應器功能並減少染色方法中的非特異性背景。在體內，抗體受益於與 Fc 結構域相關的長血漿半衰期 (t1/2)，而沒有與野生型 Fc 結構域相關的溶細胞免疫效應機制。在體外，抗體可用於流式細胞術和免疫組織化學 (IHC) 應用，以減少由 Fc 受體結合產生的非特異性背景信號。 Fc Silent™ 突變不影響抗體的其他特性，包括它們與二抗的相容性。所有 Absolute Antibody 抗體和融合蛋白均帶有 Fc Silent™ 結構域。試劑目錄包括特定物種的 Fc Silent™ 結構域，例如人類、小鼠、兔、大鼠和倉鼠

圖 2 使用表面等離子共振 (SPR) 和直接競爭性抑制 ELISA 顯示 Fc Silent™ 形式不與鼠或人 Fc 受體相互作用。該數據由 Dr.南安普頓大學的斯蒂芬·比爾斯。

免疫療法研究(Immunotherapy Research) 活體用重組抗體

針對治療研究，抗蛋白質的抗體參與co-stimulation和免疫系統調節(immune cell regulation)。 有些進入臨床階段(clinic)；更多部份仍處於研究階段。免疫細胞信號傳導(immune cell signaling)的許多方面仍然未知，Absolute Antibody開發了針對臨床相關蛋白的重組工程抗體，提供一系列免疫療法研究(Immunotherapy Research) 活體用重組抗體。

• Your favourite research tools, now updated through antibody engineering for improved performance in vivo
• Reduce immunogenicity by matching antibody species to your host organism
• Tailor effector function by choosing from our range of antibody isotypes and subtypes
• Explore new possibilities by combining two of these antibodies into a custom bispecific reagent

用於體內研究的 VivopureX™ 抗體VivopureX™ Antibodies for In Vivo Research

ivopureX™ 抗體是重組小鼠抗體，非常適合在小鼠模型中進行體內研究。該系列包括流行的抗體克隆，其中許多最初是從大鼠或倉鼠中獲得的，Absolute Antibody 已將其設計成小鼠-抗-小鼠重組版本，以改善研究結果。這些物種匹配的嵌合抗體由克隆的原始抗原結合可變結構域和小鼠恆定結構域組成。

與原始抗體形式相比，我們的 VivopureX™ 重組小鼠抗體具有許多優勢，包括：

Reduced immunogenicity: no neutralizing antibodies are induced in the host organism, meaning the antibody works for longer and cohorts respond more consistently.

Tailored effector function: antibody formats have been engineered to suit their most popular application. (Increased Fc receptor binding increases depleting potential, while reduced Fc receptor binding reduces side effects in blocking.)

Increased potency: less antibody is required to achieve the same response in mouse models.

Batch-to-batch reproducibility: recombinant production ensures the highest possible reproducibility, and guarantees high purity and low endotoxins (<0.5 EU/mg).

Antibody Name [Clone]	Engineered Format	Top Application	Available Bulk Sizes
Anti-OX40/CD134 [OX86]	Mouse IgG1	Agonism	1 mg, 10 mg, 25 mg, 100 mg
Anti-OX40/CD134 [OX86]	Mouse IgG2a	Agonism	1 mg, 10 mg, 25 mg, 100 mg
Anti-PD-1 [RMP1-14]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CTLA-4 [9D9]	Mouse IgG2a	Blocking, Treg depletion	1 mg, 10 mg, 25 mg, 100 mg
Anti-CTLA-4 [9D9]	Mouse IgG2a Fc Silent™	Blocking, peripheral Treg expansion	1 mg, 10 mg, 25 mg, 100 mg
Anti-GITR [DTA-1]	Mouse IgG2a	Agonism	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD25 [PC-61.5.3]	Mouse IgG2a	Depletion	1 mg, 10 mg, 25 mg, 100 mg
Anti-TIGIT [1B4]	Mouse IgG1	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-Lag3 [C9B7W]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD96 [6A6]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-IL-10R [1B1.3a]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-B7-H4 [7A1-6]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-BTLA [HMBT-6B2]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-Tim-4 [3A1]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-Tim-4 [5G3]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-TIM-2 [RMT2-14]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-Tim-1 [3B3]	Mouse IgG1	Agonism	1 mg, 10 mg, 25 mg, 100 mg
Anti-Tim-3 [2C12]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD115/M-CSFR [AFS98]	Mouse IgG2a	Depletion	1 mg, 10 mg, 25 mg, 100 mg
Anti-PD-L1 [10F.9G2]	Mouse IgG2b	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-PD-L1 [10F.9G2]	Mouse IgG2b Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-IFN-gamma receptor 1 [GR20]	Mouse IgG2b Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-VISTA [13F3]	Mouse IgG2b Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD20 [18B12]	Mouse IgG2a	Depletion	10 mg, 25 mg, 100 mg
Anti-CD4 epitope A [YTS 177.9]	Mouse IgG2a	Depletion	10 mg, 25 mg, 100 mg
Anti-CD4 epitope A [YTS 191.1]	Mouse IgG2a	Depletion	10 mg, 25 mg, 100 mg
Anti-CD8 alpha/Lyt-2 [YTS 169.4]	Mouse IgG2a	Depletion	10 mg, 25 mg, 100 mg
Anti-Ly6G [1A8]	Mouse IgG2a	Depletion	10 mg, 25 mg, 100 mg
Anti-CD200R [OX131]	Mouse IgG1 Fc Silent™	Blocking	10 mg, 25 mg, 100 mg
Anti-PD-L2 [TY25]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-Ly6G/Ly6C [RB6-8C5]	Mouse IgG2a	Depletion	1 mg, 10 mg, 25 mg, 100 mg
Anti-Galectin 9 [RG9-35]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD153 [RM153]	Mouse IgG2a	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD153 [RM153]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD155 [3F1]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD226 [10E5]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD45R [RA3-6B2]	Mouse IgG2a	Depletion	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD19 [6D5]	Mouse IgG2a	Depletion	1 mg, 10 mg, 25 mg, 100 mg
Anti-HVEM [HMHV-1B18]	Mouse IgG2a Fc Silent™	Blocking	1 mg, 10 mg, 25 mg, 100 mg
Anti-CD27 [RM27-3E5]	Mouse IgG1	Agonism	1 mg, 10 mg, 25 mg, 100 mg
產品貨號	Mouse target	抗體clone	Original Antibody format
Ab01052	4-1BB (CD137)	LOB12.3	Rat IgG1
Ab01054	4-1BBL (CD137L)	AT113-2	Rat IgG1
Ab00881	4-1BBL (CD137L)	TKS-1	Rat IgG2a
Ab01027	BTLA	HMBT-6B2	Hamster IgG
Ab00670	CD27	LG.3A10	Hamster IgG
Ab00895	CD27	RM27-3E5	Rat IgG2a
Ab00286	CD28	E18	Mouse IgG2b
Ab00285	CD28	D665	Mouse IgG1
Ab01109	CD40	3/23	Rat IgG2a
Ab01087	CD40L (CD154)	MR1	Hamster IgG
Ab00816	CD70	TAN 1-7	Rat IgG2a
Ab01056	CD70	TAN1-6	Rat IgG2a
Ab01028	CD80 (B7-1)	RM80	Rat IgG2a
Ab01029	CD86 (B7-2)	PO.3	Rat IgG2b
Ab01089	CD153	RM153	Rat IgG2b
Ab01297	CD96	6A6	Rat IgG2a
Ab00894	CTLA-4	9H10	Hamster IgG2
Ab01018	CTLA-4	9D9	Mouse IgG2b
Ab01088	GAL-9	RG9-35	Rat IgG2a
Ab01060	GITR	DTA-1	Rat IgG2a
Ab00374	GITR	YGITR 860.103.5	Rat IgG2b
Ab00631	GITR	YGITR765	Rat IgG2b
Ab00630	GITRL	YGL386	Rat IgG1
Ab01026	HVEM	HMHV-1B18	Hamster IgG
Ab00814	ICOS	7E.17G9	Rat IgG2b
Ab00882	ICOSL	HK5.3	Rat IgG2a
Ab01295	LAG3	C9B7W	Rat IgG1
Ab01295	LAG3	C9B7W	Rat IgG1
Ab00110	OX40 (CD134)	OX86	Rat IgG1
Ab00564	OX40L	OX-89	Rat IgG1
Ab00813	PD-1	RMP1-14	Rat IgG2a
Ab01017	PD-1H (VISTA)	mam82	Mouse IgG1
Ab01016	PD-1H (VISTA)	MH5A	Hamster IgG
Ab00373	PD-L1	YDC 127.1.1	Rat IgG2a
Ab00883	PD-L2	TY25	Rat IgG2a
Ab00875	PDPN (MAP-Tag)	PMab-1	Rat IgG2a
Ab00973	TIGIT	4D4	Hamster IgG
Ab01258	TIGIT	1B4	Mouse IgG1
Ab01032	TIM-1	3B3	Rat IgG2a
Ab01110	TIM-2	RMT2-14	Rat IgG2a
Ab01057	TIM-3	2C12	Rat IgG1
Ab01058	TIM-4	5G3	Rat IgG1
Ab01059	TIM-4	3A1	Rat IgG1